On Sept. 7, 2020, DiaSorin Molecular announced that it had received U.S. Food and Drug Administration (FDA) Clearance for its Simplexa Flu A/B & RSV Direct Gen II kit.

The Simplexa Flu A/B & RSV Direct Gen II assay provides flexibility in workflow management for the flu season as the assay can be run alone or alongside the Simplexa COVID-19 Direct kit, allowing for differential diagnosis of SARS-CoV-2, influenza A (Flu A), influenza B (Flu B), and respiratory syncytial virus (RSV).